Xencor (XNCR) Consolidated Net Income (2013 - 2026)
Xencor's (XNCR) quarterly Consolidated Net Income came in at -$128.9 million in Q1 2026, down 164.95% year-on-year from $198.5 million in Q1 2025, and down 1838.01% on a QoQ basis from -$6.7 million in Q4 2025.
Xencor (XNCR) Consolidated Net Income (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Consolidated Net Income data on file, last reported at -$128.9 million in Q1 2026.
- On a quarterly basis, Consolidated Net Income fell 164.95% year-over-year to -$128.9 million in Q1 2026; TTM through Mar 2026 was -$172.4 million, a 18.31% increase from a year earlier, with the FY2025 full-year figure at -$92.1 million, up 61.05% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$128.9 million, down from -$6.7 million in the prior quarter.
- Over the last five years, Consolidated Net Income for XNCR reached as high as $25.8 million in Q1 2022 and fell as low as -$128.9 million in Q1 2026.
- Historically, Consolidated Net Income has averaged -$42.2 million across 5 years, with a median of -$46.2 million in 2024.
- Across the five-year window, Consolidated Net Income surged 259.43% in 2022 and plunged 327.17% in 2023, its largest moves.
- Year by year, Consolidated Net Income stood at -$12.0 million in 2022, then sank by 118.49% to -$26.3 million in 2023, then sank by 75.6% to -$46.2 million in 2024, then surged by 85.6% to -$6.7 million in 2025, then plunged by 1838.01% to -$128.9 million in 2026.
- Per Business Quant data, the three most recent Consolidated Net Income figures were -$128.9 million in Q1 2026, -$6.7 million in Q4 2025, and -$6.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Xencor | 1.51 Bn | 1.13 Bn | - | -128.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.94 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -30.83 Mn |
| Mar 31, 2025 | -48.67 Mn |
| Dec 31, 2024 | -46.20 Mn |
| Sep 30, 2024 | -47.44 Mn |
| Jun 30, 2024 | -68.78 Mn |
| Mar 31, 2024 | -74.12 Mn |
| Dec 31, 2023 | -26.31 Mn |
| Sep 30, 2023 | -24.27 Mn |
| Jun 30, 2023 | -71.11 Mn |
| Mar 31, 2023 | -58.57 Mn |
| Dec 31, 2022 | -12.04 Mn |
| Sep 30, 2022 | -32.76 Mn |
| Jun 30, 2022 | -60.59 Mn |
| Mar 31, 2022 | 25.78 Mn |
| Dec 31, 2021 | 73.06 Mn |
| Sep 30, 2021 | -40.19 Mn |
| Jun 30, 2021 | -56.30 Mn |